Leonard Frank X 4

What Happened

• Leonard Frank X, CEO of NovoCure Ltd (NVCR), acquired 1,905 ordinary shares on 2026-06-30. The shares were purchased at $11.15 per share for a total reported value of $21,241. The transaction is reported as an acquisition (Transaction Code A).

Key Details

• Transaction date: 2026-06-30; Form 4 filed: 2026-07-01 (timely filing).
• Price and amount: 1,905 shares at $11.15 per share; total = $21,241.
• Plan: Shares were purchased under the 2025 NovoCure Employee Share Purchase Plan (ESPP).
• Purchase mechanics: Price was set at 85% of the closing price of NovoCure ordinary shares on 2026-01-01 (per filing footnote).
• Exemptions: The transaction is reported as exempt under Rule 16b-3(c) (per footnote).
• Shares owned after the transaction: not specified in the provided filing.

Context

• This was an ESPP purchase — a routine employee benefit that results in the insider acquiring company stock at a discount. Purchases can be interpreted differently by investors, but ESPP transactions are commonly recurring and structured by plan terms rather than discretionary open-market timing.